PUBLICATIONS

FDA Rejects Regenxbio’s Hunter Syndrome Gene Therapy: A Turning Point for the AAV Field? The recent FDA rejection of Regenxbio’s gene therapy for Hunter syndrome (MPS II) is more than a single company setback. It is a signal, and the gene therapy sector should take it seriously. Read more

Oncology CRO: A Practical RFP Guide for Sponsors and Biotech Teams What You’ll Learn in This Article Table of Contents Key Challenges in Oncology Trials and What to Expect from Your Oncology CRO Oncology CRO Evaluation Criteria Sponsors Should Prioritizeto  How to Choose the Right Oncology CRO Actionable RFP Questions for Choosing the Right Oncology CRO Common Pitfalls in Selecting an Oncology CRO (and How to Read more

Why SCOPE 2026 Felt Different for Clinical Research By Nicole Brenna, US Business Development Director at Cromos Pharma  As the 17th annual SCOPE Summit wrapped up, the energy around clinical research was unmistakable. Over four days, sponsors, CROs, sites, and technology leaders came together, offering a clear view of where the industry is heading next. Compared to last year, the mood felt more optimistic, with budgets Read more

World Cancer Day 2026: What Cancer Vaccines Have Already Achieved in Real Clinical Practice (Cancer Vaccines — Part III) In the first two parts of this series, we explored the future of cancer vaccines through the lens of technology — from the rapid rise of mRNA platforms to the renewed momentum behind DNA-based approaches. But on World Cancer Day, innovation is best measured not by promise, but by impact. Read more